Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen to reduce lipoprotein apheresis frequency in cardiovascular disease patients with elevated Lp(a)
2023-508324-35-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyperlipoproteinemia, cardiac morbidity, coronary arteriosclerosis and 3 more comparing Pelacarsen arm with Placebo arm (2 arms). Primary endpoint: Rate of lipoprotein apheresis sessions over 52 weeks. Started Apr 2024; status: completed.
02
Drugs
pelacarsen
03
Conditions
hyperlipoproteinemiacardiac morbiditycoronary arteriosclerosismyocardial infarction (MI)ischemic stroke
Beyond the preview
Go deeper on 2023-508324-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508324-35-00.